SAB Biotherapeutics, Inc.
SABSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious. The $270.7M market capitalization puts SABS squarely in micro-cap range for its industry. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Market Cap
$270.7M
Beta
0.53
P/E (TTM)
—
P/E (Fwd)
-3.61
EPS (TTM)
$-0.56
EPS (Fwd)
$-0.98
ROE
-0.3%
ROA
-25.4%
Cash
$107.4M
Total Debt
$6.2M
Free CF
-$26.6M
52W Change
37.7%
Annual Financials
Cash vs Debt
With $107.4M in cash and $6.2M in debt, SABS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$26.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -0.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, SAB Biotherapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SABS.